The Science
The prevention claim, misread: what the trials showed, what the captions say
Scroll the hashtags and the claim arrives as established fact, usually in the same sentence as a shrug emoji: Melanotan prevents skin cancer, so why is everyone so opposed? The argument does real recruiting work. A risky act becomes a health behaviour; the needle becomes prevention.
The claim is not invented from nothing. That is what makes it durable. Skin-cancer prevention was the original brief — the reason the molecule existed at all. But there is a canyon between a research goal from the 1980s and a fact you can put in a caption, and everything in the canyon is what this file is about.
Prevention was the mission, never the result
Melanotan began at the University of Arizona in the 1980s as a melanoma-prevention idea: a pharmacological tan, built before the UV ever landed, for the people who burn (where it came from). Victor Hruby’s lab engineered the analogs precisely because a sunscreen you wear can be forgotten, but a photoprotective signal you carry cannot.
That was the hypothesis. Hypotheses do not become drug claims by intention. They become drug claims through prevention trials — and no Melanotan has ever had one. The molecule’s developers abandoned MT-II as a general-use candidate decades ago. No company ever filed for a prevention indication. No regulator anywhere has ever assessed, let alone approved, Melanotan II for any use, which means the claim “prevents skin cancer” describes an event — a trial with a cancer endpoint — that has never taken place.
The caption is citing a result that does not exist.
What the tested cousin actually showed
There is exactly one approved, tested photoprotective melanocortin drug: afamelanotide, sold as Scenesse, chemically the original Melanotan I. It is worth looking precisely at what its trials measured, because the market treats them as if they measured cancer prevention. They did not.
Afamelanotide is approved for erythropoietic protoporphyria, a rare genetic disease in which visible light causes searing pain. Its Phase 3 trials enrolled 167 EPP patients and measured one thing: pain-free light exposure. Patients on the implant tolerated more light before phototoxic pain began. That is the entire approved claim, and it is a real one.
No cancer endpoint appears anywhere in that program. The EPP population largely avoids UV, which is exactly why it was usable for a safety read on chronic MC1R activation — but it also means the trials could not have shown cancer prevention even in principle. When the big 2024 review of chronic melanocortin agonism by Böhm and colleagues notes that “no melanomas were reported in the afamelanotide group,” that is a safety observation in a small, UV-avoidant population — not an efficacy finding against cancer in the general public.
The approved drug proves the target can be drugged. It proves nothing about preventing skin cancer, because nobody asked it that question.
What the laboratory evidence actually says
Here the claim has more footing than the market knows — and still less than it sells.
The underlying biology is real. Eumelanin, the brown-black pigment a tan is made of, absorbs ultraviolet light and scavenges the reactive molecules UV generates (how a tan protects skin). MC1R activation also promotes DNA repair pathways in skin cells, independent of the pigment itself. The Böhm review is candid about the direction of this evidence: melanocortin signalling is photoprotective in the laboratory sense, and compounds in this class “are being investigated as potential chemoprevention strategies.”
Then comes the sentence the captions never carry: photoprotection “may reduce the risk of melanoma but importantly does not prevent melanoma.” May reduce. Importantly does not prevent. That is the state of the art, from the review most favourable to the mechanism, in 2024.
And the real-world floor is lower than even that. Cancer Research UK puts it plainly: “having a fake or natural tan does not protect your skin from UV radiation.” A real tan provides modest protection — a sun-protection factor in the single digits, at the best estimates — against an exposure whose damage is cumulative and mutagenic. The tan is a response to damage already done, armour raised after the first blow (the tan without the sun). A melanocortin agonist can bring the armour forward in time. It cannot convert “some defence” into “prevention,” and the market’s entire pitch is that conversion.
The case reports point the other way
If the prevention claim needed a complicating document, it arrived on 7 July 2026, on the letterhead of the Skin Cancer Foundation. The Foundation issued a formal warning against Melanotan II, signed by its president, Deborah Sarnoff. It cites case reports documenting melanoma following Melanotan II use — carefully noting that case reports cannot establish causation — and then names the problem that is hardest to wave away: rapid changes in moles and pigmented lesions “that can make the detection of skin cancer more difficult.”
That is the prevention claim inverted by the dermatology literature. Melanotan II drives pigment everywhere, including in every mole (the mole problem). A mole that darkens and multiplies is harder to watch, and watching is the whole of melanoma’s early-warning system. The product does not merely fail to prove it prevents cancer. It actively degrades the surveillance that finds cancer early — while being sold, on social platforms, as prevention.
The regulatory position follows from all of it. In the UK, injectable Melanotan is illegal to sell and supply. In Australia, possession is a Schedule 9 offence. In the United States, it has never been approved for anything. The tracker keeps the dates; no jurisdiction’s file contains a prevention finding, because no jurisdiction has ever seen the evidence for one.
Why the claim keeps selling
Because it is the only version of the pitch that survives contact with the buyer’s self-image.
“Unapproved peptide, unknown contents, five-receptor flood” is a file on this site. “Skin-cancer prevention” is a reason to inject, a reason to recommend the spray to a friend, a reason to treat the warnings as interference. The claim converts the single most frightening property of the product — that it sits outside every testing system ever built — into its single most persuasive virtue: it is the protection that the system never gave you.
The structure of the distortion is consistent, and it is worth naming because it will recur. Take the one true thing — the laboratory photoprotection of the melanocortin pathway. Remove the qualifiers: may reduce, does not prevent, in the lab, never tested in people for this purpose. Move the remainder from the future tense of research into the present tense of fact. What remains is the caption.
A legitimate photoprotective agonist remains the open question this publication keeps pointing at, labeled as such. If one is ever proven to prevent anything, the proof will arrive as a trial with a cancer endpoint — the trial the prevention-trial problem explains is among the hardest in medicine. Until that result exists, “prevents skin cancer” on a Melanotan listing is not a summary of evidence. It is the 1980s mission statement, forty years orphaned from its hypothesis, still doing sales work in a caption.